Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomes

作者：Grinstein Yu I^*; Saychenko A A; Filonenko I V; Savchenko E A

来源：Cardiovascular Therapy and Prevention, 2009, 8(8): 36-43.

• Coronary heart disease
• coronary artery bypass graft surgery
• clopidogrel
• acetylsalicylic acid
• acute coronary event prevention

Aim. To study the effectiveness and safety of clopidogrel and acetylsalicylic acid (ASA) in coronary atherosclerosis (CA) patients after coronary artery bypass graft surgery (CABG) To investigate intracellular metabolic activity of platelets and its association with platelet aggregation.
Material and methods. In total, 94 45-72-year-old men with coronary heart disease (CH D) and Initially increased platelet aggregation ( P LA) were randomised into two groups, receiving clopidogrel (75 mg/d, n=44) or ASA (75-100 mg/d, n=50) The patients not responding to the two-week therapy were regarded as therapy-resistant
Results. In CHD patients after CABG. ASA resistance developed in 24% In contrast to ASA, clopidogrel action mechanisms are based on the inhibition of platelet energy metabolism, and increased substrate flow towards nonprotein synthesis in red blood cells. These features could explain the development of laboratory-diagnosed resistance for ASA, but not clopidogrel End-point analysis demonstrated that clopidogrel is more effective than ASA in the prevention of acute coronary syndrome, de novo angina, and cardiovascular death during the two-year follow-up of the post-CABG patients
Conclusion. Clopidogrel therapy was not associated with laboratory-diagnosed resistance, and was more effective in terms of acute coronary event prevention than ASA

• 出版日期2009
• 单位河北医科大学